The European Academy of Neurology Congress set the week’s agenda but the standout came from a clinic, not a podium: the first human ever dosed with a gene therapy for Cockayne syndrome. Around it, a run of FDA designations, fresh Phase 2 readouts across ALS, MS and Alzheimer’s, and a wave of neurotech launches.
readouts
actions
congress
first
A child becomes the first person ever treated with gene therapy for Cockayne syndrome
The first patient in the world has been dosed with a gene therapy for Cockayne syndrome a rare, fatal pediatric disorder that drives accelerated aging and neurodegeneration and has never had a disease-modifying treatment. Reaching a first-in-human dose doesn’t just matter for one ultra-rare disease; it resets what’s considered possible for an entire class of neuro-genetic conditions long written off as untreatable.
NeuroSense posts positive biomarker data from its Phase 2 ALS study
NeuroSense reported positive biomarker findings from the Phase 2 ROAD proof-of-concept study of PrimeC, its oral combination therapy for ALS. Biomarkers carry weight early in ALS, where they can flag disease-modifying activity long before slower functional endpoints read out.
Cognito links its Spectris device to Alzheimer’s lipid-transport biomarkers
Cognito Therapeutics presented new data showing its non-invasive gamma-sensory stimulation device, Spectris, affects lipid-transport biomarkers tied to Alzheimer’s. The findings hand a biological mechanism to a drug-free platform that has so far been chasing cognitive benefit without one.
Tiziana doses the last patient in its Phase 2 trial of intranasal foralumab for MS
Tiziana reached last-patient-dosed in the inFORM-MS trial of foralumab, an anti-CD3 antibody, in non-active secondary progressive multiple sclerosis. The novel bet is the delivery: dampening neuroinflammation through the nose rather than dosing the whole body.
Hope Biosciences publishes positive stem-cell data in chronic traumatic brain injury
Hope Biosciences published positive clinical results from its stem-cell therapy in chronic traumatic brain injury, a setting with essentially no approved options. Peer-reviewed publication lends real weight in an area where regenerative approaches have struggled to show durable benefit.
Trace Neuroscience opens a global program for its antisense candidate TRCN-1023
Trace Neuroscience launched global clinical development of TRCN-1023, an antisense oligonucleotide. The move reflects growing conviction in RNA-targeting medicines for neurological disease the same modality that already transformed spinal muscular atrophy.
Praxis wins FDA Breakthrough Therapy Designation for elsunersen in SCN2A epilepsy
Praxis Precision Medicines secured Breakthrough Therapy Designation for elsunersen, an antisense candidate for SCN2A-related developmental and epileptic encephalopathy a severe, early-onset genetic epilepsy. The designation can compress timelines and signals the agency sees early evidence of meaningful benefit.
Cemdisiran submissions accepted by both FDA and EMA in generalized myasthenia gravis
Regulatory filings for cemdisiran, an RNAi therapeutic targeting complement C5, were accepted for review by the FDA and EMA in generalized myasthenia gravis. Dual acceptance puts it on a path toward approval on both sides of the Atlantic in an increasingly crowded complement field.
Pheno Therapeutics clears an FDA IND for its lead multiple sclerosis candidate
Pheno Therapeutics cleared its IND in MS, opening the door to first-in-human testing. Each new entrant adds to a field that is shifting its ambitions from immune suppression toward remyelination and genuine neuroprotection.
Tetmedical lands Breakthrough Device status for a rapid neuro test, NSE-Fast
Tetmedical received FDA Breakthrough Device Designation for NSE-Fast, billed as the first rapid test of its kind for a neurological biomarker. Faster neuro diagnostics at the bedside could change how quickly clinicians triage brain injury and other acute conditions.
NeuroLife launches non-invasive tech to restore hand and arm movement
NeuroLife, developed at Battelle, launched a non-invasive system aimed at restoring upper-limb movement in people with paralysis. Taking neural-bypass technology out of the operating room and dropping the implant could widen access dramatically if it holds up in the clinic.
CereVasc completes enrollment in the STRIDE pivotal trial of its eShunt system
CereVasc fully enrolled STRIDE, the pivotal trial of its eShunt System an endovascular, minimally invasive alternative to traditional surgical shunts for hydrocephalus. Completing enrollment moves a less-invasive fix for a common neurosurgical problem closer to a regulatory decision.
Zeta Surgical treats its first patient with the Zeta TMS navigation system
Zeta Surgical completed first clinical use of its navigation platform for transcranial magnetic stimulation. Real-time guidance could make TMS more precise and reproducible, addressing a long-standing criticism of the therapy’s targeting.
Hyperfine builds a global council to expand portable MRI in neurosurgery
Hyperfine formed a Global Neurosurgery Advisory Council to drive broader use of its portable, point-of-care MRI. The play is about changing where brain imaging happens at the bedside and in lower-resource settings, not only in the radiology suite.
Insilico and SK Biopharmaceuticals sign an AI CNS discovery deal worth up to $2.57B
Insilico Medicine and SK Biopharmaceuticals struck an AI-powered drug-discovery collaboration worth up to $2.57 billion, centered on central-nervous-system targets. It’s among the larger CNS-focused AI deals to date though, as usual, the committed upfront is a small slice of that headline figure.
Definium Therapeutics closes an upsized $80.5M public offering
Definium closed an upsized public offering of $80.5 million to push its neuroscience pipeline forward. Pulling off an upsize in a choppy market is itself a signal of investor appetite behind the program.
Shionogi partners with the ALS/MND Natural History Consortium on real-world data
Shionogi joined the ALS/MND Natural History Consortium to gather real-world data across ALS and motor neuron disease. Natural-history data is the unglamorous infrastructure that makes the next generation of ALS trials faster and better-powered.
Brenig to present an AI-designed, brain-penetrant NLRP3 inhibitor
Brenig Therapeutics will unveil the AI-enabled design of a brain-penetrant NLRP3 inhibitor at Keystone. NLRP3 sits at the heart of neuroinflammation, and getting a selective inhibitor across the blood-brain barrier has been the hard part exactly where AI-driven design is being aimed.
Hearing-aid use linked to 23% lower dementia risk in people with epilepsy
An EAN study reported that hearing-aid use was associated with a 23% lower dementia risk among people with epilepsy. It adds to mounting evidence that treating hearing loss may be one of the more modifiable levers we have on cognitive decline.
J&J presents new IMAAVY (nipocalimab) data
Johnson & Johnson shared fresh data on IMAAVY (nipocalimab), an FcRn blocker, across its neuro-immunology indications. The readouts reinforce the case for FcRn inhibition in antibody-driven neurological diseases such as myasthenia gravis.
Lundbeck shows new Vyepti and bocunebart migraine-portfolio data
Lundbeck presented new data spanning Vyepti (eptinezumab), its anti-CGRP migraine antibody, and the earlier-stage bocunebart program. The portfolio framing signals an intent to compete across both established and next-generation migraine prevention.
When a development gets big enough, it earns a full report in The Pipeline.
Synopulse’s monthly intelligence line: deep, single-subject reports on the moves that reshape a field.